Opendata, web and dolomites

RabTarget4Metastasis SIGNED

Targeting Rab27A with covalent inhibitors for the treatment of metastatic breast cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RabTarget4Metastasis project word cloud

Explore the words cloud of the RabTarget4Metastasis project. It provides you a very rough idea of what is the project "RabTarget4Metastasis" about.

chemical    world    offers    located    regulates    led    renowned    validate    perfect    starting    hit    covalent    acts    beatson    bind    evaluation    screen    effectors    protein    switch    obtain    efficient    models    metastatic    vesicles    invasion    gtpases    tethering    transport    direct    prompt    reactivity    linklab    interaction    residues    proximity    niche    cysteines    trigger    trafficking    cruk    irreversible    metastasis    encouraging    physiological    inactive    promotion    inhibitors    undruggable    cycles    signalling    compound    cascades    therapeutic    selective    engagement    occurrence    date    exosome    qit    quantitative    glutathione    cancer    crick    gtpase    discovery    enhanced    hits    fragments    probes    potent    conserved    reducing    ppis    point    slp2    vivo    mediated    derive    active    mortality    accessed    fragment    rab27a    cells    preventing    gdp    site    effector    gsk    interfering    hence    melanosome    metastases    gtp    whilst    francis    assay    small    contribution    disruption    optimisation    suggest    causes    compounds    molecular    bound   

Project "RabTarget4Metastasis" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 224˙933 €
 EC max contribution 224˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-08-01   to  2022-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 224˙933.00

Map

 Project objective

Invasion and metastases remain to date the major causes of cancer mortality around the world. Rab27A is a small GTPase that regulates vesicles trafficking and is involved in many physiological processes, e.g. melanosome transport. Being a small GTPase, Rab27A acts as a molecular switch that cycles between an inactive state (GDP bound) and an active state (GTP bound), in which this protein is able to bind to specific effectors to trigger signalling cascades in cells. Current studies suggest a role for Rab27A in exosome-mediated pre-metastatic niche promotion. Hence, interfering with Rab27A PPIs could be effective in reducing and preventing the occurrence of metastasis in cancer. Small GTPases are renowned as challenging targets and have been long considered undruggable, but the unique presence of two non-conserved cysteines in Rab27A offers a perfect starting point for the development of selective covalent inhibitors. These residues are located in the proximity of a major interaction site with a known effector of Rab27A, Slp2, therefore encouraging for targeting PPIs. A screen of covalent fragments based on the recently developed quantitative Irreversible Tethering (qIT) assay has led to the discovery of novel hits with enhanced reactivity for Rab27A against glutathione. The current project aims to (i) obtain potent Rab27A covalent inhibitors by growing hit fragments, and (ii) demonstrate selective Rab27A target engagement in cells, and efficient disruption of the PPIs of Rab27A with its main effectors. Collaboration with the CRUK Beatson Institute will provide direct access to in vivo models to validate the contribution of Rab27A to metastatic development in cancer by use of such chemical probes, whilst state-of-the-art covalent fragment know-how will be accessed for compound optimisation at the Francis Crick Institute/GSK LinkLab, enabling prompt evaluation of the therapeutic potential of optimised lead compounds that will derive from my work.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RABTARGET4METASTASIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RABTARGET4METASTASIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

COLEX (2019)

Coopetition and Legislation in the Spanish Netherlands (1598-1665)

Read More